Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Gains from Investment Securities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Gains from Investment Securities for 5 consecutive years, with -$55000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 96.45% to -$55000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.4 million, a 38.18% increase, with the full-year FY2025 number at -$2.4 million, up 38.18% from a year prior.
  • Gains from Investment Securities was -$55000.0 for Q4 2025 at TScan Therapeutics, up from -$291000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $128361.0 in Q3 2021 to a low of -$1.5 million in Q4 2024.
  • A 4-year average of -$626932.9 and a median of -$453000.0 in 2024 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 96.45% in 2025; the steepest drop was 181.9% in 2025.
  • TScan Therapeutics' Gains from Investment Securities stood at $128361.0 in 2021, then tumbled by 752.07% to -$837000.0 in 2023, then tumbled by 85.19% to -$1.5 million in 2024, then surged by 96.45% to -$55000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Gains from Investment Securities are -$55000.0 (Q4 2025), -$291000.0 (Q3 2025), and -$786000.0 (Q2 2025).